Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great planning - conference call is full.
We are not puttering around .30 Scooter. If your jumping ship nothing that’s your call. Nothing wrong w closing your position. I’ve taken 28% off the table. Nader is Nader. Nothing new here.
Last I checked the money is green. Shows up in bank account too.
If there is one thing Nader is proficient at, its raising $.
I think we can count on the deals being even more appetizing as we move forward.
Let me tell you what kind of following and influence this tool has - zero as in nada.
Good insight A17. I’m not counting any chickens before they hatch. To be clear I am extrapolating what is currently known.
Yes, blinded placebo trials are a crap shoot if you have a borderline drug. IMHO Leronlimab is not a borderline drug. As Patterson has said patients don’t come off ventilators by chance or anecdotal reasons.
Leronlimab is the only drug in the Covid space that quiets the storm, reduces viral lode, and reduces inflammation. Patterson has stated all this many times. Now it’s time for the trials to do the talking.
I think the resistance w this drug is it just seems to all encompassing to be real. How could little CytoDyn and Nader possess such a powerful molecule? Well s#%t happens and this is powerful s#%t.
In reference to the S2C results think about what we know from the 60 EIND patients. Many were riddled w pre existing conditions and Leronlimab still saved many of those predisposed patients lives. This trial does not allow the very sick patients to participate. Nader has said there are a high number of deaths in the S2C trial.
Do you not think Leronlimab is going to show superior efficacy compared to the placebo arm? It would not surprise me if Leronlimab arm has zero to very few deaths.
With a 2:1 ratio of drug vs placebo let’s take a guess at the current 150 patients enrolled.
50 placebo - 10 deaths
100 Leronlimab - 2 deaths
That would equate to 1 death for every 10 deaths in the placebo arm.
Is that enough statistical relevance to halt the placebo arm or possibly halt the trial and grant emergency approval?
I personally don’t think those numbers are far reaching when one considers Leronlimab’s efficacy for severe patients up to this point. Just rewatch the Patterson Ted Talk and think it through again.
A17, I know you play the devils advocate w everything. Throw the devil at the S2C trial - he’s going to find a different place to play. As Lalezari has stated many times this is a home run.
The timing of this non dilutive raise points to an uplist timed w trial results. Readout from M2M and possible halting of S2C due to mobility are the 1-2 punch to fuel a successful Nasdaq uplist.
I don’t want to put the cart in front of the horse but given the Covid data up to this point I would be shocked w anything short of amazing trial results. Dr. Patterson’s extreme confidence coupled w Dr. Lalezari’s home run opinion isn’t based on hype it’s based on blood work and firsthand knowledge. IMO the S2C death rate in the placebo arm compared to the drug arm is going to be so lopsided even Fauchi will have to take notice not o mention the FDA.
The terms of this latest raise is placing $28.5M in Naders hands and ultimately costing 2.85M shares. Just last year that would have cost SH’s a shade under 100M shares plus warrants. That’s a helluva deal for the company and it’s SH’s at this juncture and IMO gets us off the OTC.
The stars have aligned and anyone betting against this company is going to get run over. Let the fear mongers monger. Tick-Tock.
Well said Smiley. Truly an honor to be associated w a big thinker. Tomorrow is full of the unexpected so be expecting.
Yes, WE, the loyal SH’s are there. The naysayers and bottom feeders will never change there agenda. It’s just the way the game is played.
A clear thinkers conviction will be tested resulting in stronger conviction. This is similar to a really taught novel that becomes more captivating with each page turned. Only difference is this no novel it’s the real deal.
Been through it before and that’s what happened. I’m not an expert here just going w past experience.
No your correct, but cusip will change. That is different.
The uplist requires a new cusip which means the shorts are hosed as they will have to close their books and start over. Hopefully it will catch them w their pants down and the SP gets some payback from the Citron back stabbing.
Thanks for setting the record straight Black Ops. Just the facts. You summarized precisely what transpired that cut CYDY’s valuation in half in a blink.
Was the landscape ripe for a manipulative short attack? Yes. Would a chart and a peaking RSI point to a high probability for a correction? Yes.
The issue here is the techniques and the misuse of false information that was assembled to crash the SP. Perception is reality in life and the stock market is a glaring example. Truth is not reality. Reality is whatever one is lead to believe in their mind at a particular moment regardless of the authenticity of the information. This type of deception is about creating a false perception and then supporting that deception with an event that validates the deception. In this case an organized sell off to create massive panic.
We’ve all seen this scenario numerous times where integrity and honesty is sacrificed for financial gain. When big $ is accessible people don’t play fair they play ugly. The big rub is when dishonesty affects saving lives and the hoodwinking of SH’s — then it becomes personal and deep seeded.
Citron should be fined and shut down and Andrew Left should be held accountable by the SEC. The message should be: Knowingly printing false information for the purpose of defrauding is a lifetime sentence in terms of future business applications in the financial markets. With Left’s history he should be lambasted. Instead there is no message from the SEC other than we choose to allocate our resources on more pressing matters. It’s a hear no evil see no evil look the other way policy.
The truth is, this is the underbelly of the financial markets where shorting has become the smart play. No wonder why most people think the stock market is rigged and Wall Street can’t be trusted. Because it can’t.
That will make this victory all the sweeter given the mine field that CYDY and our multi indication molecule is navigating. We have come such a long way and are now so close to kicking the door down. We are like the “Little Engine that Could”.
Totally agree. I think CYDY SP is driven up and down by the strength of the news. The current trading range validates the fact that the market is waiting for M2M read out. I think we may see a run up just prior to release as there is always somebody in the know that leaks.
All good points. Nobody said it was going to be a cake walk. It’s the reality of the landscape. That’s why the SP is where it is - the risk you explained. Covid is the catalyst that has a high probability of totally derisking CYDY.
“I have to look up the NP/Real Time conversion rate daily to determine its value.”
Good one Latane. LMAO!
Thanks for posting the equation that determines Leronlimab’s Trial success. This is where the rubber hits the road. I plugged my numbers in and I’m sleeping quite well in anticipation of the full read out.
Your welcome. Couldn’t be more bullish at this juncture.
This lawsuit will have no impact in uplist. The plaintiffs are not ignorant as they own millions of shares.
They consulted legal council to insure this would not impact Nasdaq application for uplist.
It has nothing to do w this investment. The tell is there is a lack of any substantive negative info.
In respect to SP predictions if Leronlimab was to receive emergency approval the betting line would be interesting.
One aspect of the market that is a given is its unpredictability. The holy grail has been to create some formula that can reduce that unpredictability factor.
Charts are one source. Historical data is another. With the Covid factor comes a different animal. A high level of irrational exuberance, momentum, and a ton of emotion.
That’s why the SP could bolt into the mid 20’s with approval. That’s the pop on news that correlates w the sentiment that is building up w the increasing uncertainty surrounding Covid.
Your contrarian perspective in relationship to the overwhelming bullish perspective on this board is a positive as it makes investors contemplate more aggressively why they they own this investment.
The result is they are convinced even more then before this is a very rare investment w tremendous upside over both the short term and long.
Thank you for your posts Hopester they are a blessing in disguise.
In 30 seconds.
Good strategy Grip,
Fundamentals are strong. Gap between now and M2M read out is where the mind can wander and falsehoods can creep in w a pullback. If one forgets what they hold and lacks discipline they get caught second guessing themselves. That is the beginning of the buying high / selling low trap.
My takeaway from Nader’s comments is a confidence in Emergency IND approval for unmet need. Most likely coming from the S2C half way point (195 patients) based on mortality. It’s not out of the question w the M2M trial but IMO unlikely.
Interesting the Nasdaq uplist could come at the same time as the S2C interim. What a 1-2 punch that would be. I can’t even speculate as to where the SP would land.
All in all there is much reason to believe in the upcoming data from both trials given the data from the 60 EIND patients. If your a believer the current SP is a gift.
Looks like Naders talk at the SH’s meeting is having a bullish impact. The SP is going vertical.
IMO todays SH’s meeting is old news. Increase to 800M AS is a forgone conclusion. Market knows it.
In regards to releasing M2M partial results it won’t matter once the rest of the data is released. Nader took a chance by deciding to go early w safety thinking the market would translate the data into a telegraph on efficacy. It actually worked but the AF hit piece was ready for Nader’s play. So the battle continues with AF’s personal dislike for Nader. At the end of the day I predict that AF finally gets his ass kicked three ways to Sunday. He will not be able to disprove the science which is his forte.
The focus is on the news that is going to move the stock forward or backwards. We all know what that is in the short term. What we don’t know is the exact date or the strength of the data. The market currently has handicapped the outcome as of this moment at 5.72. That’s w the shorts having got the last punch in.
I’m looking for momentum to return as the market looks towards the complete M2M read out.
Don’t sweat it.
People overreact and assume anyone being objective or asking questions on this message board has a hidden agenda. Personally I could give a crap if someone is short and they are questioning this investment. I’ve seen a number of those exact people shift to neutral and then Long after drilling down on Leronlimab. The deeper one investigates the more they scratch their head in astonishment — even the most skeptical. The proof is the resiliency despite hit piece after hit piece fails to bury the stock. If Leronlimab was a fake we’d be at 20 cents.
We are moving to a new level of intensity as the clinical results are marching towards disclosure. Regardless of how positive and convincing they are AF and the likes will burn the midnight oil figuring a way to spin fear and doubt to the detriment of progress and humanity. That’s the way the game is played as the stakes increase. The O’Mighty $ and fear of possible redistribution of wealth becomes more important than doing the right thing and saving lives. The system will be tested once again but this time under the Covid spotlight.
I see a growing army of support that is drafting behind a cause that has great purpose with a fearless leader that is going to campaign until justice is served.
I am all in and more than confident in the data that will be coming, especially from the S2C trial.
The unforced errors are what bother me. It’s just sloppy business practice.
Could not agree more Sara. For whatever reason Nader does not get it. The BOD should be leaning hard on this issue. It’s management 101. I have beat this like a dead horse for years and refuse to speculate further because it makes no logical sense that THEY can’t get it right.
Here’s the rub. Nader is a gun slinger and shoots from the hip w no fear. He’s dangerous but he’s effective in selling the story. I’ve watched him do this gig for a long time.
The issue is the company PR’s are very important in terms of accurately and unambiguously representing the facts. CYDY gets an F for their performance on this front. That’s on Nader and the BOD. Why would anybody with half a brain want to piss on there hard work. No excuses — get it right.
Ok, so I’ve been harping on this issue for years and now we are preparing to take center stage. I am baffled that w all the marbles that are on the table Scott Kelly isn’t stepping up to nip this in the bud.
It’s called leadership and strong language to confront the problem. Looks to me like Nader has the BOD in his pocket and they jump when he says so.
Message to the BOD—wake the F up.
It’s pure lunacy. I don’t even bother to read the posts.
Lawman,
Very nice job calling AF out. His personal vendetta against CYDY is one based on fiction yet again. He really is eating himself out over his dislike of Nader and Leronlimab.
I believe you put the big cheese right in the mouse trap. His ego is bigger than his brain and he is chasing a loosing proposition.
Nothing will give me more satisfaction than seeing him get beaten to a pulp. You delivered a strong blow and now he’s wobbling and ripe for a KO.
Whoever has the powers to be please sticky so all can understand the misinformation he has built his undermining sleeze ball thesis on.
Fair enough Evil. Just my take after seven years.
AF ALWAYS purposely deceives his targeted audience. That’s his bread and butter. Making a mountain out of nothing burgers. One of the most effective twister of information of all time. What a way to make a living. I stay the hell away from people that live on the dark side.
A little pull back and then the reality of the payload within the rocket will prevail.
“How hard is it for some people understand basic English?”
Really hard for the people that are trying to learn Biotech in the midst of deception by a very crafty mudslinger. AF is going to do what he does because his ego is so big he’d rather chase a loosing proposition than pack up and move on.
https://emerginggrowth.com/stat-news-adam-feuerstein-uses-up-his-nine-lives-on-cytodyn-otcqb-cydy/
One has to have tremendous stamina and ignorance to continue to make a case that CYDY and Leronlimab are nothing more than a fraud and snake oil.
In the real world they are a necessary component to prove just how rock solid the very sand they are standing in is actually concrete when mixed with water. Better move those feet before they turn into concrete goulashes - the tide is coming in and I hear it’s going to be one of the highest of the year.
Longs are standing on solid ground.